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New treatment combination for testicular cancer
High-dose chemotherapy with carbo-
platin and etoposide followed by hae-
mopoietic rescue with peripheral-blood 
stem-cell transplantation (PBSCT) is 
eﬀ ective in recurrent testicular cancer 
(N Engl J Med 2007; 357: 340–48).
“Switching to PBSCT [from bone 
marrow transplantation] reduced cost, 
converted [the procedure] to outpatient 
therapy, and allowed rapid haematolog-
ical engraft ment, allowing the second 
course of high-dose chemotherapy to 
be given just 3–4 weeks after the ﬁ rst 
course”, says author Lawrence Einhorn 
(Indiana University, Bloomington, IN, 
USA).
The researchers analysed records 
from  184 patients with metastatic 
germ-cell tumours, who relapsed after 
receiving cisplatin-containing chemo-
therapy. 173 patients had received 
two courses of high-dose carbo-
platin (700 mg/m2) and etoposide 
(750 mg/m2) for 3 days, each 
followed by an infusion of stem cells. 
11 patients received one course. 
116 patients had com plete remission 
(median follow-up=48 months, range 
14–118). 104 patients showed remis-
sion beyond 2 years. Remission was 
higher with high-dose chemotherapy 
used as second-line compared with 
third-line chemotherapy.
“Since the potential to cure patients 
after they fail standard therapy without 
transplant is limited, the results oﬀ er 
hope in this young population of 
patients”, says Manish Kohli (University 
of Rochester Medical Center, NY, USA)
“The report excludes the highest-risk 
patients with mediastinal primaries 
and cisplatin-refractory tumours”, 
says Guru Sonpavde (US Onco logy 
Research, Houston, TX, USA). “Studies 
in the past have shown durable 
response in this group with paclitaxel 
incorporated chemo therapy.” He 
continues, “conventional chemo-
therapy (paclitaxel, ifosfamide, 
cisplatin) has outcomes comparable 
to transplantation in relapsed patients 
with good risk. Therefore, the necessity 
of transplantation in a good risk 
population can only be answered with 
randomised trials”.
Kaushal Raj Pandey
Peripheral-blood stem-cell transplantation reduces costs
Imatinib challenge dismissed in India
On August 6, 2007, the Madras High 
Court in India dismissed Novartis’ chal-
lenge to an Indian law that does not 
allow patents for minor modiﬁ cations 
to known compounds. Charities cam-
paign ing to increase ac cess to medicines 
welcome the dec ision. “This ruling 
gives the clear guidance needed for 
the Indian patent oﬃ  ces to assess the 
thousands of drug pat ent applications 
pending before them”, says Ellen t’Hoen 
of Médecins Sans Frontières. 
The base compound at the centre of 
this legal battle, imatinib, was patented 
worldwide in 1993. India had no 
patent protection for drugs until the 
Indian Patents Act 2005, which allows 
patents for compounds that represent 
new inventions since 1995. Thus 
Indian companies can make generic 
versions of imatinib by engineering 
slight modiﬁ cations to the mol ecule 
that might not be considered to be a 
new invention. 
In January, 2006, the Indian Patent 
Oﬃ  ce disallowed a patent for Novartis’ 
Glivec (imatinib) because it did not 
satisfy the requirements of Section 3(d) 
of the Indian Patents Act 2005—this 
section denies patents on the basis of 
trivial modiﬁ cations of existing com-
pounds (known as ‘ever greening’).
In August, 2006, Novartis challenged 
this decision in the Madras High Court 
and asked it to declare Section 3(d) 
unconstitutional and in breach of 
India’s obligation under the Trade-
related Aspects of Intellectual Property 
Rights agreement. The court ruled that 
it had no jurisdiction on whether Indian 
patent laws were complying with rules 
set by the World Trade Organisation.
Carrie Scott from Novartis says, “there 
are in adequacies in Indian patent law 
that will have long-term consequences 
for patients. India’s patent system 
[needs to be] strengthened so that 
in cen tives are in place to bring 
patients…new and better medicines”.
According to Brian Druker (Oregon 
Health and Science University Cancer 
Institute, Portland, OR, USA), “the 
most important issue is access to drugs 
at aﬀ ordable prices. Novartis would 
argue that they already provide free 
[imatinib] to 7000 patients in India 
through the Glivec International Patient 
Assistance Program. While this is to be 
commended, I estimate this covers less 
than 5% of patients in India who need 
the drug”. However, he adds that as 
India’s pharmaceutical industry expands 
and seeks to export its products abroad 
it might fall foul of it’s own rules, “if 
patents can be cir cum vented by slight 
modiﬁ cations as occurred here, it 
would mean that a drug generated by 
an Indian company would be subject 
to the same erosion of mar ket share by 
other companies”.
Khabir Ahmad
